ArchivesBiological Science Disciplines: All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.PubMed: A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.Apicomplexa: A phylum of unicellular parasitic EUKARYOTES characterized by the presence of complex apical organelles generally consisting of a conoid that aids in penetrating host cells, rhoptries that possibly secrete a proteolytic enzyme, and subpellicular microtubules that may be related to motility.Directories as Topic: Lists of persons or organizations, systematically arranged, usually in alphabetic or classed order, giving address, affiliations, etc., for individuals, and giving address, officers, functions, and similar data for organizations. (ALA Glossary of Library and Information Science, 1983)Purine-Pyrimidine Metabolism, Inborn ErrorsPyrimidine Nucleotides: Pyrimidines with a RIBOSE and phosphate attached that can polymerize to form DNA and RNA.Purines: A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.Publishing: "The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.AlaskaSeeds: The encapsulated embryos of flowering plants. They are used as is or for animal feed because of the high content of concentrated nutrients like starches, proteins, and fats. Rapeseed, cottonseed, and sunflower seed are also produced for the oils (fats) they yield.Chromatography, Ion Exchange: Separation technique in which the stationary phase consists of ion exchange resins. The resins contain loosely held small ions that easily exchange places with other small ions of like charge present in solutions washed over the resins.N-Glycosyl Hydrolases: A class of enzymes involved in the hydrolysis of the N-glycosidic bond of nitrogen-linked sugars.Adenosine: A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.Molecular Weight: The sum of the weight of all the atoms in a molecule.Peas: A variable annual leguminous vine (Pisum sativum) that is cultivated for its rounded smooth or wrinkled edible protein-rich seeds, the seed of the pea, and the immature pods with their included seeds. (From Webster's New Collegiate Dictionary, 1973)Chromatography, Gel: Chromatography on non-ionic gels without regard to the mechanism of solute discrimination.Electrophoresis, Polyacrylamide Gel: Electrophoresis in which a polyacrylamide gel is used as the diffusion medium.Thionucleosides: Nucleosides in which the base moiety is substituted with one or more sulfur atoms.Organophosphonates: Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P=O)O2 structure.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Amination: The creation of an amine. It can be produced by the addition of an amino group to an organic compound or reduction of a nitro group.Molecular Structure: The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.Structure-Activity Relationship: The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.Stereoisomerism: The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)Drug Delivery Systems: Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.Alkylation: The covalent bonding of an alkyl group to an organic compound. It can occur by a simple addition reaction or by substitution of another functional group.Organophosphorus Compounds: Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS.United States National Aeronautics and Space Administration: An independent Federal agency established in 1958. It conducts research for the solution of problems of flight within and outside the Earth's atmosphere and develops, constructs, tests, and operates aeronautical and space vehicles. (From U.S. Government Manual, 1993)National Library of Medicine (U.S.): An agency of the NATIONAL INSTITUTES OF HEALTH concerned with overall planning, promoting, and administering programs pertaining to advancement of medical and related sciences. Major activities of this institute include the collection, dissemination, and exchange of information important to the progress of medicine and health, research in medical informatics and support for medical library development.Surgical Mesh: Any woven or knit material of open texture used in surgery for the repair, reconstruction, or substitution of tissue. The mesh is usually a synthetic fabric made of various polymers. It is occasionally made of metal.United StatesNational Health Insurance, United StatesPolypropylenes: Propylene or propene polymers. Thermoplastics that can be extruded into fibers, films or solid forms. They are used as a copolymer in plastics, especially polyethylene. The fibers are used for fabrics, filters and surgical sutures.MEDLARS: A computerized biomedical bibliographic storage and retrieval system operated by the NATIONAL LIBRARY OF MEDICINE. MEDLARS stands for Medical Literature Analysis and Retrieval System, which was first introduced in 1964 and evolved into an online system in 1971 called MEDLINE (MEDLARS Online). As other online databases were developed, MEDLARS became the name of the entire NLM information system while MEDLINE became the name of the premier database. MEDLARS was used to produce the former printed Cumulated Index Medicus, and the printed monthly Index Medicus, until that publication ceased in December 2004.Waiting Lists: Prospective patient listings for appointments or treatments.Th2 Cells: Subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.Libraries, MedicalIsosorbide: 1,4:3,6-Dianhydro D-glucitol. Chemically inert osmotic diuretic used mainly to treat hydrocephalus; also used in glaucoma.Coated Materials, Biocompatible: Biocompatible materials usually used in dental and bone implants that enhance biologic fixation, thereby increasing the bond strength between the coated material and bone, and minimize possible biological effects that may result from the implant itself.Illusions: The misinterpretation of a real external, sensory experience.Polymers: Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS).Friction: Surface resistance to the relative motion of one body against the rubbing, sliding, rolling, or flowing of another with which it is in contact.Neural Networks (Computer): A computer architecture, implementable in either hardware or software, modeled after biological neural networks. Like the biological system in which the processing capability is a result of the interconnection strengths between arrays of nonlinear processing nodes, computerized neural networks, often called perceptrons or multilayer connectionist models, consist of neuron-like units. A homogeneous group of units makes up a layer. These networks are good at pattern recognition. They are adaptive, performing tasks by example, and thus are better for decision-making than are linear learning machines or cluster analysis. They do not require explicit programming.Tissue Engineering: Generating tissue in vitro for clinical applications, such as replacing wounded tissues or impaired organs. The use of TISSUE SCAFFOLDING enables the generation of complex multi-layered tissues and tissue structures.Tissue Scaffolds: Cell growth support structures composed of BIOCOMPATIBLE MATERIALS. They are specially designed solid support matrices for cell attachment in TISSUE ENGINEERING and GUIDED TISSUE REGENERATION uses.Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
(1/16) Introduction of a fluorine atom at C3 of 3-deazauridine shifts its antimetabolic activity from inhibition of CTP synthetase to inhibition of orotidylate decarboxylase, an early event in the de novo pyrimidine nucleotide biosynthesis pathway.

 (+info)

(2/16) Dual effects of pyrazofurin and 3-deazauridine upon pyrimidine and purine biosynthesis in mouse L1210 leukemia.

Pyrazofurin (NSC 143095) as the monophosphate derivative is a potent inhibitor of orotidine 5'-monophosphate (OMP) decarboxylase of the pyrimidine pathway and has been proposed to inhibit 5-aminoimidazole-4-carboxamide ribotide (AICAR) transformylase (EC 2.1.2.3) of the purine pathway (J. F. Worzalla, and M. J. Sweeney, Pyrazofurin inhibition of purine biosynthesis via 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl 5'-monophosphate formyltransferase. Cancer Res., 40: 1482-1485, 1980). Measurement of levels of pyrimidine and purine intermediates in cultured mouse L1210 leukemia cells has shown that 25 microM pyrazofurin induces an 8-fold accumulation of OMP and large accumulations of intermediates proximal to the blockade with abrupt decreases in uridine and cytidine nucleotides. Considerable increases in the cellular concentrations of N-succino-AICAR (SAICAR), AICAR, 5-formamidoimidazole-4-carboxamide ribotide (FAICAR), IMP, XMP, and GMP at later times indicate that AICAR transformylase is not significantly inhibited in cultured cells; rather the purine pathway and the GMP branch are stimulated. However, addition of 25 microM 3-deazauridine (NSC 126849) to leukemia cells did result in inhibition of AICAR transformylase: AICAR and SAICAR accumulated, IMP disappeared and there was a large accumulation of guanosine nucleotides. Blockade of pyrimidine biosynthesis by derivatives of pyrazofurin or 3-deazauridine spares 5-phosphoribosyl-1-pyrophosphate and L-glutamine, elevated concentrations of which may stimulate initial reactions of purine biosynthesis and the reaction XMP----GMP.  (+info)

(3/16) Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.

When incubated with 1-beta-D-arabinofuranosylcytosine (ara-C), RPMI 6410 cells formed a hitherto unrecognized ara-C metabolite, 1-beta-D-arabinofuranosylcytosine diphosphate choline. This compound was characterized by (a) chromatographic behavior, (b) chemical and enzymatic hydrolysis, (c) phosphorus content, and (d) incorporation of [5-3H]ara-C and [methyl-14C]choline. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline by RPMI 6410 cells was enhanced in the presence of 3-deazauridine (DU) and was preceded by that of 1-beta-D-arabinofuranosylcytosine triphosphate. The antiproliferative effects of ara-C and DU toward RPMI 6410 cells were potentiated when the agents were present together. The anabolism of ara-C during a 24-hr interval of culture was markedly enhanced by the presence of DU; cellular concentrations of 1-beta-D-arabinofuranosylcytosine triphosphate and 1-beta-D-arabinofuranosylcytosine diphosphate choline were 5- and 15-fold higher than those in the absence of DU. This enhancement appears to be the basis of the potentiation of cytotoxicity resulting from combination of the agents. Pretreatment of RPMI 6410 cells with DU resulted in enhanced rates of cellular uptake of ara-C. ara-C uptake under these circumstances was blocked by the inhibitor of nucleoside transport, nitrobenzylthioinosine.  (+info)

(4/16) Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.

1-beta-D-Arabinofuranosylcytosine diphosphate choline was formed from 1-beta-D-arabinofuranosylcytosine (ara-C) during incubation in vitro of peripheral myeloblasts from patients with acute myelogenous leukemia and cultured cells (nonleukemic human lymphocytes, mouse lymphoma L5178Y, and HeLa); as well, 1-beta-D-arabinofuranosylcytosine diphosphate choline was formed in vivo in mouse leukemia L1210 cells and mouse liver. 3-Deazauridine enhanced the anabolism of ara-C in nonleukemic lymphocytes in vitro and leukemia L1210 cells in vivo but did not influence ara-C anabolism in the other cell types. In acute myelogenous leukemia myeloblasts incubated in vitro with ara-C, concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate were maximal after 8 hr of incubation and formation of the latter preceded that of 1-beta-D-arabinofuranosylcytosine diphosphate choline.  (+info)

(5/16) Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells.

Because alterations in cell membrane sialoglycoconjugates can affect the behavior of neoplastic cells, we investigated the effects of in vitro treatment with antimetabolites used in cancer therapy on the expression of membrane sialic acid in cultured HL-60 leukemic cells. In these studies, cells were incubated with Vibrio cholerae neuraminidase to remove surface sialic acid. Reappearance of membrane sialic acid during drug treatment was followed (a) by measuring changes in radioactive surface labeling of viable cells with sodium metaperiodate-sodium[3H]-borohydride, (b) by measuring the decline in accessible surface galactosyl receptor sites which occurred coincident with membrane sialic acid replacement, and (c) by measuring the incorporation of [3H]glucosamine into membrane-associated neuraminidase-labile sialic acid. We were especially interested in learning whether drugs that affect intracellular pools of cytidine triphosphate (CTP), an important nucleotide intermediate in sialylation reactions, could inhibit regeneration of membrane sialic acid. 3-Deazauridine, a competitive inhibitor of CTP synthetase, depleted CTP pools and curtailed surface membrane resialylation with little or no effect on synthesis of de novo sialic acid from precursor sugars. The addition of cytidine restored CTP pools and sialic acid regeneration. Acivicin, a glutamine antagonist, also depleted CTP pools and curtailed surface membrane resialylation. In addition, it retarded de novo synthesis of sialic acid. The addition of cytidine restored intracellular CTP pools and sialic acid regeneration. However, both cytidine and guanosine were required to restore sialic acid synthesis from precursor sugars. 1-beta-D-Arabinofuranosylcytosine, a competitive inhibitor of sialic acid synthetase and of sialyltransferase, inhibited both de novo sialic acid synthesis and membrane resialylation. Only the latter effect was reversed by the addition of exogenous cytidine. Hydroxyurea, an agent shown previously to inhibit glycoconjugate production in hamster fibroblasts, curtailed membrane resialylation and de novo synthesis of sialic acid without depleting CTP pools. Doxorubicin, at levels that caused marked arrest of cell proliferation, had no effect on sialic acid synthesis or expression on the membrane surface. These data suggest that antimetabolites, apart from their cytotoxic effects or effects on cellular growth, may directly inhibit the expression of membrane sialic acid.(ABSTRACT TRUNCATED AT 400 WORDS)  (+info)

(6/16) Drug sequence-dependent toxicity and small bowel mucosal injury in mice treated with low doses of 3-deazauridine and 1-beta-D-arabinofuranosylcytosine.

The toxicity to mice of combinations of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine was investigated. The drugs were administered daily i.p. on Days 1 to 5, each drug at 10 mg/kg body weight; these dosages are small fractions of the dosages at which 10% of the treated animals died when either drug was administered alone on the foregoing schedule. This drug combination was severely toxic when 3-deazauridine was administered 2 to 8 hr prior to 1-beta-D-arabinofuranosylcytosine; most mice treated in this way died within 3 days of the last treatment. Histological examination showed that severe damage to the small bowel mucosa resulted from treatment with the drugs in the above, lethal sequence. In contrast, treatments with this drug combination at the same dosages were tolerated when the two agents were administered simultaneously or when 1-beta-D-arabinofuranosylcytosine preceded 3-deazauridine. Under the latter conditions, small bowel mucosal injury was much less severe. Female mice were more sensitive to the toxic treatment regimen than were male mice and were protected against the latter when either the 3-deazauridine or the 1-beta-D-arabinofuranosylcytosine component was preceded by treatment with nitrobenzylthioinosine (100 mg/kg), a potent inhibitor of nucleoside transport.  (+info)

(7/16) Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells.

The biochemical and biological effects of the combination of 5-aza-2'-deoxycytidine (5-aza-dCyd) and 3-deazauridine (3-DU) on L1210 leukemic cells and EMT6 tumor cells were investigated. The cytotoxic action of 5-aza-dCyd and 3-DU on both L1210 and EMT6 cells in vitro was synergistic when these agents were used in combination. The combination of 5-aza-dCyd and 3-DU produced a greater inhibition of in vitro growth of L1210 and EMT6 cells than did either agent alone. The in vivo antineoplastic activity of this combination was synergistic with respect to the increased survival time of BALB/c x DBA/2 F1 mice with L1210 leukemia. 3-DU, an agent that reduces the intracellular pool size of cytosine nucleotides, stimulated the incorporation of [3H]-5-aza-dCyd into DNA of both L1210 and EMT6 cells, suggesting that the synergistic action of this combination is related to the increased incorporation of 5-aza-dCyd in the presence of 3-DU.  (+info)

(8/16) Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid.

The antitumor agent 3-deazauridine (DAU) was administered rapidly to four patients before surgical removal of intracerebral tumor. Tumor, adjacent brain tissue, and temporalis muscle were assayed for DAU by high-pressure liquid chromatography. DAU penetrated comparably into tumor, brain, and muscle; in one patient, tissue concentrations were higher than concurrent plasma concentrations. The active metabolite 3-deazauridine 5'-triphosphate was quantitated in one tumor sample and greatly exceeded its Ki for cytidine 5'-triphosphate synthetase. DAU was also present in autopsy brain specimens from two patients treated shortly antemortem. Cerebrospinal fluid concentrations were 22.1 and 59.0%, respectively, of concurrent plasma concentrations during continuous infusion of DAU in two patients. Cerebrospinal fluid concentration was 3.1 microgram/ml 2 hr after a 30-min infusion of 1.5 g of drug per sq m and fell to 1.9 microgram/ml at 16 hr. Thus, DAU is capable of penetrating into intracerebral tumor, brain, and cerebrospinal fluid and is worthy of investigation in the treatment of intracerebral and meningeal neoplasms.  (+info)

*  List of MeSH codes (D13)
3' untranslated regions MeSH D13.444.735.544.875.885 --- 5' untranslated regions MeSH D13.444.735.615 --- rna, neoplasm MeSH ... 3' untranslated regions MeSH D13.444.735.790.878.885 --- 5' untranslated regions MeSH D13.444.735.828 --- rna, viral MeSH ... 3-deazauridine MeSH D13.570.800.892.628 --- pseudouridine MeSH D13.570.800.892.800 --- tetrahydrouridine MeSH D13.570.800.892. ... 3-thiotriphosphate) MeSH D13.695.667.454.504.400 --- guanylyl imidodiphosphate MeSH D13.695.667.454.525 --- 5'-guanylic acid ...
CEISAM->Equipe...  CEISAM->Equipe...
Hemisynthesis of 2,3,4-(13)C3-1,4-Androstadien-3,17-dione: A Key Precursor for the Synthesis of (13)C3-Androstanes and (13)C3- ... Practical Pd/C-Catalysed Suzuki-Miyaura Reactions for the Preparation of 3-Aryl-4-oxypyridin-2(1H)-ones, 3-Aryl-2,4- ... ACS OMEGA, 3 (8), 9155-9159, doi, ImpFact5: not available. An Autonomous Self-Optimizing Flow Reactor for the Synthesis of ... ORGANIC LETTERS, 20 (3), 792-795, doi, ImpFact5: 6.492. One-Pot Synthesis of Functionalized Fused Furans via a BODIPY-Catalyzed ...
more infohttp://www.sciences.univ-nantes.fr/CEISAM/index.php?page=249&lang=FR
Woodman D[au] - PubMed - NCBI  Woodman D[au] - PubMed - NCBI
Effects of 2-deoxy-D-glucose and 3 deazauridine individually and in combination on the replication of Japanese B encephalitis ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Woodman+D%5Bau%5D&dispmax=50
TCDB » SEARCH  TCDB » SEARCH
2.A.41.2.3. Pyrimidine-preferring nucleoside:Na+ symporter, CNT1 (Na+/nucleoside = 2)(transports uridine, gemcitabine and 5'- ... 2.A.41.1.3. The purine nucleoside uptake transporter NupG (YxjA) (Johansen et al., 2003) ... Solute carrier family 28 member 3 (Concentrative Na+-nucleoside cotransporter 3) (CNT 3) (hCNT3). This protein is distinct from ... Broadly selective nucleoside:Na+ cotransporter, hfCNT (transports uridine, thymidine, inosine, 3'-azido-3'deoxythymidine, 2'3' ...
more infohttp://tcdb.org/search/result.php?tc=2.A.41.1
US Patent for Pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use Patent (Patent # ...  US Patent for Pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use Patent (Patent # ...
ethyl-β-carboline-3-carboxylate Antagonists Prostaglandins PGE1, PGE2, PGI2 Anticonvulsants hydantoins such as phenytoin, ... cytarabine), 3-deazaguanine, dihydro-5-azacytidine, tiazofurin, sangivamycin, Ara-A (vitarabine), 6-MMPR, PCNU, FENU, HENU, ... 24 (3): 356-363.. *Haspel, H. C., Stephenson, K. N., Davies-Hill, T., El-Barbary, A., Lobo, J. F., Croxen, R. L., Mougrabi, W ... Berl) 147(3):217-249 (1999).. *Wang et al., "Conjugation patterns of endogenous plasma catecholamines in human and rat," J. Lab ...
more infohttps://patents.justia.com/patent/9023818
Rhode Island Mesothelioma Information | Surviving Mesothelioma  Rhode Island Mesothelioma Information | Surviving Mesothelioma
3-DAU pretreatment for 2 hours increases inhibitory activity of Ara-C 35 fold. The in vivo studies using ATS-mouse xenografts ... Two chemotherapeutic combinations, 2′-deoxycoformycin (DCF) plus 8-azaadenosine (8-Aza-Ado) or formycin and 3-deazauridine (3- ... 3). Fiber dosimetry and biologic markers of response will be compared following intrapleural injection and inhalation of ... 3) To determine whether asbestos-activated macrophages stimulate invasion of preneoplastic and neoplastic mesothelial cells; 4 ...
more infohttps://survivingmesothelioma.com/mesothelioma-locations/mesothelioma-united-states/rhode-island/
Ctps cytidine 5-triphosphate synthase [Mus musculus (house mouse)] - Gene - NCBI  Ctps cytidine 5'-triphosphate synthase [Mus musculus (house mouse)] - Gene - NCBI
Introduction of a fluorine atom at C3 of 3-deazauridine shifts its antimetabolic activity from inhibition of CTP synthetase to ... Introduction of a fluorine atom at C3 of 3-deazauridine shifts its antimetabolic activity from inhibition of CTP synthetase to ... Title: Introduction of a fluorine atom at C3 of 3-deazauridine shifts its antimetabolic activity from inhibition of CTP ...
more infohttps://www.ncbi.nlm.nih.gov/gene/?term=51797
Stent coated with a sustained-release drug delivery and method for use thereof - Psivida Inc.  Stent coated with a sustained-release drug delivery and method for use thereof - Psivida Inc.
Example 3. A mixture of 3.3 gm Chronoflex C(65D) (Lot# CTB-G25B-1234) dispersion containing 0.3 gm of Chronoflex C(65D) and 2.2 ... 3. The device of claim 1, which provides sustained release of the therapeutically active form of A for a period of at least 24 ... 3, which shows the total cumulative release of TC-112 from PVA coated glass plates. The slope of the curve demonstrates that TC ... Three (3) Stents, supplied by Guidant Corp, were coated then with the polymer /TC-32 solution by dipping and followed by air- ...
more infohttp://www.freepatentsonline.com/7279175.html
L-Glutamine - DrugBank  L-Glutamine - DrugBank
3. Completed. Treatment. Infant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / ... 3. Completed. Treatment. Sickle Cell Disorders / Sickle ß0-Thalassemia. 1. 3. Recruiting. Treatment. Acute Kidney Injury (AKI) ... 3. Completed. Treatment. Critical Illness / Infection Complication / Inflammatory Reaction / Multiple Organ Failure / Nutrition ... 2, 3. Terminated. Treatment. Critical Illness / Respiratory Insufficiency / Sepsis. 1. 3. Active Not Recruiting. Supportive ...
more infohttps://www.drugbank.ca/drugs/DB00130
Cyclophosphamide, Adriamycin, vincristine, and dexamethasone in the treatment of bulky central nervous system lymphoma |...  Cyclophosphamide, Adriamycin, vincristine, and dexamethasone in the treatment of bulky central nervous system lymphoma |...
3.. Herbst KD, Corder MP, Justice GR: Successful Therapy with Methotrexate of a Multicentric Mixed Lymphoma of the Central ... Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KD, Burgess MA, Loo TL: Penetration of 3- ... Deazauridine into Human Brain, Intracerebral Tumor, and Cerebrospinal Fluid. Cancer Research 39: 4119-4122, 1979PubMedGoogle ... The other 5 patients all had rapid marked shrinkage of tumor, but 3 developed progression or appearance of meningeal disease. ...
more infohttps://rd.springer.com/chapter/10.1007/978-1-4613-2297-9_59
Targeting Purine and Pyrimidine Metabolism in Human Apicomplexan Parasites  Targeting Purine and Pyrimidine Metabolism in Human Apicomplexan Parasites
2004;20(3):109-112. [PubMed]. [175] Martin RE, Henry RI, Abbey JL, Clements JD, Kirk K. Genome Biol. 2005;6(3) art. no.-R26. [ ... 2004;3(2):245-254. [PMC free article] [PubMed]. [200] De Koning HP, Al-Salabi MI, Cohen AM, Coombs GH, Wastling JM. Int. J. ... 1996;3(10):881-887. [PubMed]. [234] Heroux A, White EL, Ross LJ, Kuzin AP, Borhani DW. Structure. 2000;8(12):1309-1318. [PubMed ... 2002;13(3):167-172. [PubMed]. [253] Rubin H, Salem JS, Li LS, Yang FD, Mama S, Wang ZM, Fisher A, Hamann CS, Cooperman BS. Proc ...
more infohttp://pubmedcentralcanada.ca/pmcc/articles/PMC2720675/
Ornithine Decarboxylase 1 (ODC1) ELISA Kits  Ornithine Decarboxylase 1 (ODC1) ELISA Kits
Introduction of a fluorine atom at C3 of 3-deazauridine shifts its antimetabolic activity from inhibition of CTP synthetase ( ...
more infohttps://www.antibodies-online.com/abstract/Ornithine+Decarboxylase+1+
Anna Karlsson | Profilsida | Karolinska Institutet  Anna Karlsson | Profilsida | Karolinska Institutet
GENOMICS 2006;87(3):410-6. N-1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. Hernandez ... 3 '-[4-Aryl-(1,2,3-triazol-1-yl)]-3 '-deoxythymidine Analogues as Potent and Selective Inhibitors of Human Mitochondrial ... GENOMICS 1996;38(3):450-1. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human ... Reviews on recent clinical trials 2006;1(3):185-92. New ultrasensitive P-32-postlabelling method for the analysis of 3,N-4- ...
more infohttps://ki.se/people/annkar
List of MeSH codes (D13) - Wikipedia  List of MeSH codes (D13) - Wikipedia
3' untranslated regions MeSH D13.444.735.544.875.885 --- 5' untranslated regions MeSH D13.444.735.615 --- rna, neoplasm MeSH ... 3' untranslated regions MeSH D13.444.735.790.878.885 --- 5' untranslated regions MeSH D13.444.735.828 --- rna, viral MeSH ... 3-deazauridine MeSH D13.570.800.892.628 --- pseudouridine MeSH D13.570.800.892.800 --- tetrahydrouridine MeSH D13.570.800.892. ... 3-thiotriphosphate) MeSH D13.695.667.454.504.400 --- guanylyl imidodiphosphate MeSH D13.695.667.454.525 --- 5'-guanylic acid ...
more infohttps://en.wikipedia.org/wiki/List_of_MeSH_codes_(D13)
Oncotarget | Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated...  Oncotarget | Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated...
Yi-Dong Hong1,2,*, Jian Zhang3,*, Ming Zhuang1,*, Wei Li4, Puy-Uan Wu5, Ru-Tian Li5, Nan Hu1, Bao-Xiang Bian1, Zi-Yan Song1 and ... Figure 3: MKN45 (A) and MKN28 (B) cells were treated with Rhodamine-B-loaded NPs and TNPs, respectively. Fluorescent signals ... 3. Ebert MP, Tänzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day C, Rosenberg R, Reinacher- ... 2013; 5:3.. 22. Lirk P, Berger R, Hollmann MW, Fiegl H. Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid ...
more infohttp://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=21274&path%5B%5D=67693
ADDITIONAL CHARACTERIZATION OF ADENOSINE NUCLEOSIDASE FROM ALASKA PEA SEEDS  ADDITIONAL CHARACTERIZATION OF ADENOSINE NUCLEOSIDASE FROM ALASKA PEA SEEDS
A 3-fold purification has been reached with a 0.56 % recovery. The purification scheme involved ammonium sulfate precipitation ... The substrate specificity of the enzyme was investigated using 2'-deoxyinosine, allopurinol riboside, 3-deazauridine, and ...
more infohttp://jewlscholar.mtsu.edu/handle/mtsu/5446
ADDITIONAL CHARACTERIZATION OF ADENOSINE NUCLEOSIDASE FROM ALASKA PEA SEEDS  ADDITIONAL CHARACTERIZATION OF ADENOSINE NUCLEOSIDASE FROM ALASKA PEA SEEDS
A 3-fold purification has been reached with a 0.56 % recovery. The purification scheme involved ammonium sulfate precipitation ... The substrate specificity of the enzyme was investigated using 2'-deoxyinosine, allopurinol riboside, 3-deazauridine, and ...
more infohttp://jewlscholar.mtsu.edu/handle/mtsu/5382
Partners, technologies & platforms  Partners, technologies & platforms
3. To construct databases (chemical libraries) that allow efficacious handling of the data generated and extraction of ... We perform first-rate pre-clinical (7 Tesla Bruker) and clinical (3 Tesla Siemens) research using structural and functional MRI ... This invention concerns new family of C3-arylated-3-deazauridine with potent anti-HSV activities and negligible cytotoxicity ... The laboratory is equipped with 3 high resolution gamma spectrometry detectors, 1 Nal gamma spectrometry detector for measuring ...
more infohttp://www.transbio-sudoe.eu/find-partner-technology.php?n=179&esp=2&MotsATrouver=&TypeRech=
Partners, technologies & platforms  Partners, technologies & platforms
3. To construct databases (chemical libraries) that allow efficacious handling of the data generated and extraction of ... We perform first-rate pre-clinical (7 Tesla Bruker) and clinical (3 Tesla Siemens) research using structural and functional MRI ... This invention concerns new family of C3-arylated-3-deazauridine with potent anti-HSV activities and negligible cytotoxicity ... The laboratory is equipped with 3 high resolution gamma spectrometry detectors, 1 Nal gamma spectrometry detector for measuring ...
more infohttp://www.transbio-sudoe.eu/find-partner-technology.php?n=160&esp=2&MotsATrouver=&TypeRech=
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations | BMC Cancer | Full Text  Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations | BMC Cancer | Full Text
1995;22:3-10.Google Scholar. *. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C ... 3). Previously, Flores et al. described that p53 requires TAp73 and/or TAp63 for DNA damage-induced cell death, whereas TAp73 ... Meijer A, Kruyt FA, van der Zee AG, Hollema H, Le P, ten Hoor KA, Groothuis GM, Quax WJ, de Vries EG, de Jong S. Nutlin-3 ... 3 RUNX2 prohibits pro-apoptotic TAp63 in p53-mutated pancreatic cancer cells. RUNX2 collaborates with mutant p53 to inhibitpro- ...
more infohttps://0-bmccancer-biomedcentral-com.brum.beds.ac.uk/articles/10.1186/s12885-018-4217-9
VU Biochemijos institutas  VU Biochemijos institutas
Biologija 3:10-12. * Semėnaitė, R., R. Gasparavičiūtė, R. Duran, S. Precigou, L. Marcinkevičienė, I. Bachmatova, and R. Meškys. ... Biologija 3:13-15. * Ger, M., V. Tunaitis, and M. Valius. 2003. Elucidation of the complex formation between Nck-α, RasGTPase ... Biologija 3:53-55. * Klausa, V., L. Piešinienė, J. Staniulis, and R. Nivinskas. 2003. Abundance of T4-type bacteriophages in ... Biologija 3:3-6. * Piešinienė, L., A. Zajančkauskaitė, L. Truncaitė, and R. Nivinskas. 2003. Analysis of sequence-specific ...
more infohttp://www.bchi.vu.lt/index.php?id=21_4
  • We perform first-rate pre-clinical (7 Tesla Bruker) and clinical (3 Tesla Siemens) research using structural and functional MRI, resonance spectroscopy, molecular imaging, image processing among other MR techniques. (transbio-sudoe.eu)
  • Often after 3-5 years of treatment patients reportedly develop complex dose-related unpredictable response fluctuations leading to a progressive decrease in therapeutic efficacy and also possible onset of serious side effects such as abnormal involuntary movements, end-of-dose deterioration and abrupt near instantaneous on-off changes in patient disability. (justia.com)
  • For instance, hypermethylation of the transcription factor AP-2 epsilon (TFAP2E) affects the therapeutic efficacy of 5-FU based chemotherapy in colorectal cancer [ 3 ] and GC [ 4 ]. (oncotarget.com)
  • 3. The device of claim 1, which provides sustained release of the therapeutically active form of A for a period of at least 24 hours, and, over the period of release, the concentration of the prodrug eluting from polymer is less than 10% of the concentration of the therapeutically active form of A. 4. (freepatentsonline.com)
  • The hypermethylation decreases TFAP2E expression and consequently increases expression of its downstream target dickkopf homolog 4 protein (DKK4), which is related to 5-FU resistance [ 3 , 4 ]. (oncotarget.com)
  • The other 5 patients all had rapid marked shrinkage of tumor, but 3 developed progression or appearance of meningeal disease. (springer.com)
  • For AML 3 cells, the com bination of five AZA CdR, GSK 126, and TSA showed a similar synergistic interaction in a colony assay because the triple blend that contained DZNep. (bossforum.net)
  • Solute carrier family 28 member 3 (Concentrative Na + -nucleoside cotransporter 3) (CNT 3) (hCNT3). (tcdb.org)
  • The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. (healthmatics.info)